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Daratumumab is an antibody currently used in the treatment of 
patients with refractory multiple myeloma. Blood samples from 
patients being treated with daratumumab may show panreactivity 
during pre-transfusion testing. To facilitate the provision of 
blood components for such patients, it is recommended that a 
baseline phenotype or genotype be established prior to starting 
treatment with daratumumab. If patient red blood cells (RBCs) 
require phenotyping after the start of daratumumab treatment, 
dithiothreitol (DTT) treatment of the patient’s RBCs should 
be performed. The medical charts of four patients treated with 
daratumumab were reviewed. The individual number of doses 
ranged from 1 to 14; patient age ranged from 55 to 78 years; two 
men and two women were included in the review. Type and screen 
data were obtained from samples collected over 33 encounters 
with a range of 1 to 13 encounters per patient. All samples were 
tested initially by automated solid-phase testing. Any reactivity 
with solid phase led to tube testing with either low-ionic-
strength saline, polyethylene glycol, or both. If incubation failed 
to eliminate the reactivity, the sample was sent to a reference 
laboratory for DTT treatment and phenotyping. Of the 33 samples 
tested, 23 (69.7%) samples had reactivity in solid-phase testing. 
In 8 of the 10 samples that did not react in solid-phase, testing 
was conducted more than four half-lives after the last dose of 
daratumumab. Of the 23 that had reactivity in solid-phase, 16 
(69.6%) samples demonstrated loss of reactivity using common 
laboratory methods. For the seven patients whose sample 
reactivity was not initially eliminated, six were provided with 
phenotypically matched blood based on prior molecular testing. 
Only one sample was sent out for DTT treatment. These results 
suggest that daratumumab interference with pre-transfusion 
testing can be addressed using common laboratory methods. This 
finding could save time and money for laboratories that do not 
have DTT available. Immunohematology 2017;33:22–26.
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Multiple myeloma is a malignancy of plasma cells that 
highly express CD38. There have been many improvements 
in patient survival recently with the advent of new treatment 
strategies, although many patients still die from refractory 
disease.1 Targeted therapies are highly sought after to improve 
treatment and minimize toxicity.2 Daratumumab is an IgG1k 
monoclonal antibody that binds CD38 and is currently 
used in the treatment of refractory multiple myeloma.1,3 
The attachment of the therapeutic antibody may induce 
tumor killing via antibody-mediated complement activation, 
antibody-dependent cell-mediated cytotoxicity, antibody-
dependent cellular phagocytosis, or direct effects of blocking 
the antigen function.4
In brief, human CD38 is a 45-kDa single-chain 
transmembrane glycoprotein with a single membrane-
spanning region. In adults, the CD38 protein is present on the 
majority of natural killer cells, T cells, B cells, monocytes, and 
macrophages and to some extent on platelets and red blood 
cells (RBCs). CD38 is diffusely expressed on hematopoietic 
cells early in their differentiation, and expression levels decline 
on many cells lines as the cells terminally differentiate. The 
exception to this is plasma cells, where CD38 becomes more 
strongly expressed. CD38 shares structural homology with 
adenosine diphosphate (ADP)-ribosyl cyclase. ADP-ribosyl 
cyclase catabolizes nicotinamide adenine dinucleotide (NAD) 
to cyclic ADP ribose (cADPR), a naturally occurring metabolite 
of oxidized NAD (NAD+) that serves as a second messenger for 
Ca2+ mobilization from intracellular sites. With this function, 
CD38 plays a role in protein phosphorylation, inflammation/
cell growth/differentiation, and cell attachment.5
CD38 also has weak expression on RBCs; as a result of 
this expression, it has been demonstrated that this therapeutic 
antibody may cause agglutination during pre-transfusion 
testing.2–4 This reactivity has been reported to occur in a 
variety of media, including low-ionic-strength saline (LISS) 
and polyethylene glycol (PEG), as well as various test methods 
(solid-phase, tube, and gel). This interfering reactivity can 
be found when using antihuman globulin (AHG) in pre-
transfusion testing of such patients’ plasma or serum (indirect 
antiglobulin test [IAT]; namely, antibody detection testing, 
antibody identification panels, and AHG crossmatches) 
and/or testing of the patient’s RBCs (auto control and direct 
antiglobulin test [DAT]). It has been noted that this reactivity 
is generally weak (1+) but may be stronger in solid-phase 
testing.3,6,7 Studies that have reported this interfering reactivity 
in a variety of media have not tried multiple media on a single 
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sample. There is also much variability within the literature as 
to the frequency of this interfering reactivity in the various 
media. Additionally, it is not known how comorbidities or 
other medications may influence the interference that is seen. 
Substances that interfere with pre-transfusion testing have 
the potential to cause increased patient morbidity, mortality, 
and costs. These substances have the potential to mask a 
clinically relevant antibody.  In addition, attempts to remove 
interfering reactivity from the patient’s RBCs might disturb 
the antigen structure to the degree that phenotyping may 
be indeterminate. There are also increased costs associated 
with resolving the panreactivity caused by this interfering 
substance, as well as potential delay for patients to receive the 
transfusion components they need.
It is recommended that a baseline phenotype or genotype 
of the patient’s RBCs be established prior to the patient starting 
treatment with daratumumab so that, if needed, phenotype-
matched, antigen-negative blood can be provided. However, 
if the patient’s RBCs require phenotyping after the start of 
daratumumab, routine dithiothreitol (DTT) treatment of 
these RBCs should be performed.3,6 This method was recently 
evaluated and supported in an international validation.7 Using 
DTT as the principle strategy for eliminating this interfering 
reactivity requires additional steps. DTT is a thiol-based 
reagent that cleaves sulfhydryl bonds and is commonly used 
when testing samples with cold agglutinins to disrupt the 
structure of IgM so possible underlying clinically significant 
IgG antibodies may be found.8 Several antigens, including 
CD38, contain sulfhydryl bonds that are susceptible to this 
reagent, which is the basis for using DTT as a treatment to 
eliminate this reactivity. Some notable antigens with disulfide-
exposed bonds include those in the Kell, Lutheran, Landsteiner-
Wiener, and YT blood group systems.3 Serologic typing for 
these antigens may show false-negative results as a byproduct 
of using DTT treatment to eliminate CD38 reactivity. 
Additionally, DTT is not routinely used in many hospital-
based blood banks, necessitating send-out testing, which may 
be costly and time-consuming. Although aliquots of DTT 
are available for a relatively small acquisition cost, there are 
other costs to consider: additional technician time to perform 
DTT treatment, time required to create and implement 
new protocols, special disposal of reagents, and issues 
with reimbursement between in-house testing and send-
out testing. Another factor to consider is the small number 
of patients receiving daratumumab at an institution. After 
carefully considering all of these factors, we decided that it was 
more cost-effective for our lab to send out samples for DTT 
treatment than to perform DTT treatment in-house.
At our institution, genotyping results can take up to 
2 weeks to receive and cost $975 plus the additional $97/
antigen/unit for antigen-negative blood. DTT treatment may 
take several days for a result and costs our laboratory $1450 
for each treatment. Another proposed strategy is the use of 
antibodies with specificity against CD383,6 as well as using 
panels with cord blood cells.9 These antibodies and panels, 
also, are not widely available.
Our institution is a 676-bed academic, tertiary-care 
hospital in the Midwest, surrounded geographically by low-
population-density rural areas. We have an active solid organ 
and bone marrow transplant program. In a typical year, we 
perform approximately 26,000 type and screen tests with a 
staff of 18 full-time employees. 
We propose an alternative initial strategy for dealing with 
daratumumab interference that meets our institution’s needs 
and may be helpful for other similarly situated institutions. 
Both solid-phase and gel testing are known to enhance 
serologic reactivity. Retesting samples, that were initially 
reactive by solid-phase or gel testing with tube testing using 
various media or incubation times to identify whether the 
reactivity persists, is a strategy implemented to address 
nonspecific reactivity in many testing algorithms for various 
interfering substances.10 Rather than routinely moving to DTT 
treatment after identifying initial panreactivity with a three-
cell antibody screen (as is currently recommended), we moved 
to tube testing with various media or incubation times to 
determine if the use of DTT is routinely warranted for testing 
samples from patients who are receiving daratumumab.
Materials and Methods
To evaluate if standard laboratory methods were 
effective in eliminating the interfering reactivity caused by 
daratumumab, the medical charts of patients being treated 
with daratumumab (dose 16 mg/kg) were reviewed. The 
inclusion criterion for review was patients being treated 
with daratumumab for multiple myeloma that needed pre-
transfusion testing. The review included four patients, two 
men and two women, ranging in age from 55 to 78 years. The 
individual number of doses ranged from 1 to 14. Type and 
screen data were collected from 33 blood samples collected 
from these four patients, with each patient contributing from 1 
to 13 samples. All samples were initially tested by automated 
solid-phase testing (Galileo Echo, Immucor, Norcross, GA) 
using a three-cell antibody screen (Capture-R Ready Screen 
3, Immucor) following the manufacturer’s instructions. The 
agglutination strength by solid-phase testing was graded via 
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the analyzer’s interpretation algorithm. The agglutination 
strength for the tube testing was graded via methods 1–9 of 
the AABB Technical Manual.10 Any reactivity by solid-phase 
testing led to additional tube testing with either LISS, PEG, or 
both. With continued reactivity, tube testing with a 60-minute 
incubation with no enhancement was done. 
For the tube testing with enhancement, two drops of 
patient plasma or serum and one drop of thoroughly mixed 
antibody screening cells were added to their respective 
tubes. Then, two drops of PEG or LISS were added to each 
tube and mixed. The tubes were incubated at 37°C ± 1°C for 
10–30 minutes. If no enhancement was used, the tubes were 
incubated at 37°C ± 1°C for 60 minutes.
When PEG was used, the tubes were washed four times 
in an automated cell washer, after which two drops of AHG 
reagent was added. The tubes were then mixed, centrifuged, 
and read for agglutination. When LISS or no enhancement 
was used, the tubes were centrifuged and read after incubation, 
and washed in an automated cell washer four times, followed 
by the addition of two drops of AHG reagent. The tubes were 
mixed, centrifuged, and read again for agglutination.
When the reactivity persisted, the sample was sent out for 
DTT treatment and genotyping. In addition, the results were 
compared with those from samples tested from their last dose 
of daratumumab (half-life 21 days). 
The DTT treatment was done using 0.2 M DTT, which 
was prepared by dissolving chemical (powdered) DTT in 
phosphate-buffered saline, pH 8.0. The DTT solution was then 
divided into 1-mL aliquots that were stored at –18°C. 
Prior to DTT treatment, panel cells and control (K–k+) 
cells were washed in saline once. Four volumes of 0.2 M DTT 
was added to one volume of test RBCs. The tubes were then 
mixed well and incubated at 37°C ± 1°C for 30 minutes. After 
the incubations, the treated RBCs were washed in normal 
saline (pH 7.3) and resuspended to 3–5 percent.
Quality control of the prepared DTT reagent was performed 
by testing DTT-treated and -untreated (K–k+) cells with anti-k 
antisera to ensure that the DTT was functioning as expected. 
The patient’s serum or plasma sample was then tested with 
the 0.2 M DTT-treated cells using antibody identification 
methods such as tube, gel, or solid-phase.
Genotyping was carried out by our local reference 
laboratory (HEA Bead Chip, Immucor) following the 
manufacturer’s instructions.
Results
Of the 33 samples tested, 23 (69.7%) had reactivity in solid-
phase testing (Table 1). It was noted that 8 of the 10 samples 
that did not react by solid phase were collected more than four 
half-lives after the last dose of daratumumab. Results of the 
remaining two samples were reported as uninterpretable; the 
automated solid-phase analyzer generated a report of “results 
failed” due to operational error. 
The 23 samples with solid-phase reactivity were 
then tested with other methods. Sixteen (69.6%) samples 
demonstrated loss of panreactivity using common laboratory 
methods. There were seven samples in which the reactivity 
was not initially eliminated. For the patients associated with 
six of these samples, either phenotypically matched blood 
from prior testing was provided or the transfusion was no 
longer indicated. Only one sample was sent for DTT treatment. 
For patient 1, elimination of the interfering reactivity was 
seen with the use of LISS on the first sample, and a genotype 
was obtained. On testing of the sixth and seventh samples, the 
reactivity could not be eliminated, and antigen-negative blood 
was provided based on the initial genotyping, eliminating the 
need for costly DTT treatment. For samples 8–11, reactivity 
was present and was eliminated using common laboratory 
methods. On testing of the twelfth sample, the initial solid-
phase testing was negative; this sample was collected 4.3 half-
lives from the patient’s last dose.
For patient 2, the interfering reactivity could not be 
eliminated in the first sample. There was not enough sample 
left to send for DTT treatment, and a redraw could not be 
obtained. On testing of the second sample, the reactivity 
remained, but a transfusion was no longer clinically indicated. 
On testing of samples 3–7, the reactivity was eliminated with 
common laboratory methods. The sixth sample required DTT 
treatment, and a genotype was performed.  On testing the 
ninth and tenth samples, the reactivity remained, and antigen-
negative blood was provided. Because of the implementation 
of this study within routine clinical laboratory processes, a 
60-minute incubation was not done on these two samples. 
The reactivity seen in samples 11–13 was eliminated with 
common laboratory methods.
The first sample from patient 3 showed interfering 
reactivity, but a transfusion was no longer clinically indicated. 
On testing of the second sample, the reactivity was eliminated 
with common laboratory methods. The remainder of the 
samples were negative by the initial solid-phase testing despite 
all of them being collected within two half-lives of the patient’s 
last dose.
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treatment Half-lives¶Panel 1 Panel 2 Panel 3 Panel 1 Panel 2 Panel 3 Panel 1 Panel 2 Panel 3
1 1 4+ 4+ 4+ W+ W+ W+ 0 0 0 NT No —
 2 3+ 2+ 3+ 0 0 0 0 0 0 NT No —
 3 4+ 3+ 3+ 0 0 0 NT NT NT NT No —
 4 3+ 3+ 3+ 2+ 2+ 2+ 0 0 0 NT No —
 5 4+ 4+ 3+ 0 0 0 NT NT NT NT No —
 6 3+ 4+ 3+ 2+ 2+ 2+ 2+ 2+ 2+ NT No —
 7 3+ 4+ 3+ W+ W+ W+ 2+ 2+ 2+ NT No —
 8 4+ 3+ 3+ 1+ 1+ 1 0 0 0 NT No —
 9 3+ 3+ 2+ 0 W+ 0 W+ W+ W+ All negative No —
 10 2+ 3+ 3+ NT NT NT 1+ 2 2+ All negative No —
 11 1+ 1+ 0 NT NT NT 0 0 0 NT No 3
 12 0 0 0 NT NT NT NT NT NT NT No 4.3
2 1 3+ 4+ 3+ 2+ 1+ W+ 2+ 2+ 2+ W+ No —
 2 3+ 3+ 1+ 1+ 1+ 1+ 1+ 1+ 1+ NT No —
 3 3+ 3+ 3+ 0 0 0 NT NT NT NT No —
 4 3+ 4+ 3+ W+ 1+ 0 W+ W+ W+ All negative No —
 5 3+ 3+ 2+ 2+ W+ 1+ 1+ W+ W+ All negative No —
 6 3+ 2+ 1+ 3+ 3+ 3+ 2+ 2+ 2+ All negative Yes —
 7 3+ 2+ 0 0 0 0 NT NT NT NT No —
 8 3+ 2+ 0 2+ 2+ 2+ 1+ 2+ 1+ All positive No —
 9 1+ 2+ 2+ W+ 1+ 1+ W+ W+ W+ NT No —
 10 3+ 3+ 3+ 1+ W+ 1+ 0 1+ 1+ NT No —
 11 3+ 2+ 2+ MF 2+ W+ W+ W+ W+ All negative No —
 12 4+ 3+ 3+ 0 0 0 0 W+ W+ NT No —
 13 2+ 3+ 3+ 0 0 0 NT NT NT NT No —
3 1 Results failed W+ 1+ 1+ 0 1+ 1+ W+ No —
 2 Results failed NT NT NT 0 0 0 NT No ~1
 3 0 0 0 0 0 0 NT NT NT NT No —
 4 0 0 0 NT NT NT NT NT NT NT No —
 5 0 0 0 NT NT NT NT NT NT NT No —
 6 0 0 0 NT NT NT NT NT NT NT No —
 7 0 0 0 NT NT NT NT NT NT NT No —
 8 0 0 0 NT NT NT NT NT NT NT No —
4 1 0 0 0 NT NT NT NT NT NT NT No 8
*Initial antibody detection by solid-phase testing using reagent antibody screening cells from three cell lines. Reaction grading results were provided by the 
automated solid-phase analyzer’s interpretation algorithm.
†Additional tube testing using PEG and LISS.
‡Additional tube testing using 60-minute incubation with no enhancement.
§Reaction grading results for tube testing were done according to Methods 1–9 in the AABB Technical Manual, 18th ed.10
¶Number of half-lives since last collected sample.
PEG = polyethylene glycol; LISS = low-ionic-strength saline; DTT = dithiothreitol; W+ = weak positive; NT = not tested; MF = mixed-field reactivity.
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There was only one sample tested from patient 4, and it 
was negative on the initial solid-phase screen. Though this 
patient’s sample did not have any reactivity by any test method, 
the results were included to highlight the relationship between 
the timing of daratumumab treatment and the presence of 
interfering reactivity. This sample was collected eight half-
lives from the patient’s last dose.
Conclusions
Here we demonstrate that using multiple standard 
laboratory methods may obviate the need for routine 
DTT treatment up to 70 percent of the time. Under the 
current recommendations, the majority of samples with 
daratumumab-related reactivity would have needed either 
send-out testing or in-house DTT treatment. We propose that 
obtaining a baseline RBC phenotype or genotype from the first 
patient sample combined with the use of standard laboratory 
methods can be a more efficient and cost-effective strategy 
than directly moving to DTT treatment.
Accurate pre-transfusion testing is necessary for patient 
safety. Being able to manage samples with daratumumab-
related reactivity in an efficient and cost-effective manner that 
still allows for detection of clinically significant alloantibodies is 
important for patient care. DTT treatment, although effective, 
may add significant cost and increased turnaround time for 
patients. Although a complete cost comparison and analysis 
is beyond the scope of this report, one can appreciate that for 
a laboratory similar to ours, using DTT testing as the primary 
method to manage samples with daratumumab-induced 
reactivity could prove to be costly. Each laboratory needs to 
consider their workflow and patient population to determine if 
bringing DTT treatment in-house is cost-effective.
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